MYOM2 and Miyoshi myopathy: Despite the subgroup analysis limited to the small sample size, the remission depth of the 13 responders was independent with the baseline MM burden, BCMA+ and CS1+ ratio of MM cells, the baseline levels of sBCMA in PB and BM, serum M protein, albumin, β macroglobulin, and LDH, R-ISS staging, the treatment history of ASCT, CAR-T cells, and daratumumab, but correlated to the baseline levels of serum IL-6 and IL-10 (Table S4).